ATE333277T1 - Behandlung von dyskinesie - Google Patents

Behandlung von dyskinesie

Info

Publication number
ATE333277T1
ATE333277T1 AT00972966T AT00972966T ATE333277T1 AT E333277 T1 ATE333277 T1 AT E333277T1 AT 00972966 T AT00972966 T AT 00972966T AT 00972966 T AT00972966 T AT 00972966T AT E333277 T1 ATE333277 T1 AT E333277T1
Authority
AT
Austria
Prior art keywords
dyskinesia
treatment
compounds
histamine receptor
activation
Prior art date
Application number
AT00972966T
Other languages
English (en)
Inventor
Jonathan Brotchie
Michael Hill
Alan Crossman
Original Assignee
Motac Neuroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Motac Neuroscience Ltd filed Critical Motac Neuroscience Ltd
Application granted granted Critical
Publication of ATE333277T1 publication Critical patent/ATE333277T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Resistance Heating (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00972966T 1999-10-22 2000-10-20 Behandlung von dyskinesie ATE333277T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9924941.9A GB9924941D0 (en) 1999-10-22 1999-10-22 Treatment of dyskinesia

Publications (1)

Publication Number Publication Date
ATE333277T1 true ATE333277T1 (de) 2006-08-15

Family

ID=10863143

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00972966T ATE333277T1 (de) 1999-10-22 2000-10-20 Behandlung von dyskinesie

Country Status (13)

Country Link
US (1) US7935718B2 (de)
EP (1) EP1223930B1 (de)
JP (1) JP5175015B2 (de)
AT (1) ATE333277T1 (de)
AU (1) AU782357B2 (de)
CA (1) CA2389476C (de)
CY (1) CY1106194T1 (de)
DE (1) DE60029463T2 (de)
DK (1) DK1223930T3 (de)
ES (1) ES2267581T3 (de)
GB (1) GB9924941D0 (de)
PT (1) PT1223930E (de)
WO (1) WO2001030346A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5392770A (en) * 1993-06-29 1995-02-28 Clawson; Burrell E. Tubing circuit systems for humidified respiratory gas
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
WO2005097111A2 (en) * 2004-03-26 2005-10-20 Merck & Co., Inc. Treatment of tremor with histamine h3 inverse agonists or histamine h3 antagonists
EP1707203A1 (de) * 2005-04-01 2006-10-04 Bioprojet Verwendung von Alkylaminen, die kein Imidazole enthalten, als Histamin H3 Rezeptor Liganden, zur Behandlung von Morbus Parkinson, obstruktiver Schlafapnoe, vaskularer Demenz, Demenz mit Lewy Korpen
DE102005029468A1 (de) * 2005-06-24 2006-12-28 Plt Patent & Licence Trading Ltd. Verwendung von Inhibitoren der N-Methyltransferasen in der Therapie des Parkinson-Syndroms
MX2009011449A (es) * 2007-04-24 2010-01-25 Toray Industries Agente terapeutico o profilactico para disquinesia.
US11426366B2 (en) 2015-05-15 2022-08-30 Arizona Board Of Regents On Behalf Of The Universsity Of Arizona Compositions and methods for treating motor disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586562B1 (fr) * 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
US4816456A (en) * 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
US5091428A (en) * 1987-04-24 1992-02-25 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
US5821259A (en) * 1991-11-12 1998-10-13 Theoharides; Theoharis C. H3 -receptor agonists as therapeutic agents
WO1993012108A1 (en) * 1991-12-18 1993-06-24 Schering Corporation Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
AU4078997A (en) * 1996-08-22 1998-03-06 New York University Cholinesterase inhibitors for treatment of parkinson's disease
US6028169A (en) 1997-03-31 2000-02-22 Human Genome Sciences, Inc. Chemokine β-6 antagonists
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
AU757749B2 (en) * 1998-10-07 2003-03-06 Ortho-Mcneil Pharmaceutical, Inc. Isolated DNA encoding human H3 histamine receptor
US6136559A (en) * 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US6316475B1 (en) * 2000-11-17 2001-11-13 Abbott Laboratories Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications
US7754210B2 (en) * 2002-06-25 2010-07-13 Xu Kai Y Inotropic antibodies and therapeutic uses thereof
ES2285245T3 (es) * 2002-09-13 2007-11-16 Motac Neuroscience Limited Tratamiento de la disquinesia con 2,3-benzodiazapinas.
AU2003267557B2 (en) * 2002-09-17 2009-02-26 Motac Neuroscience Limited Treatment of dyskinesia

Also Published As

Publication number Publication date
AU782357B2 (en) 2005-07-21
JP5175015B2 (ja) 2013-04-03
AU1152301A (en) 2001-05-08
JP2003512428A (ja) 2003-04-02
PT1223930E (pt) 2006-12-29
US20050245587A1 (en) 2005-11-03
GB9924941D0 (en) 1999-12-22
EP1223930B1 (de) 2006-07-19
ES2267581T3 (es) 2007-03-16
DE60029463T2 (de) 2007-02-15
CA2389476C (en) 2010-03-09
EP1223930A1 (de) 2002-07-24
WO2001030346A1 (en) 2001-05-03
DE60029463D1 (de) 2006-08-31
CY1106194T1 (el) 2011-06-08
CA2389476A1 (en) 2001-05-03
DK1223930T3 (da) 2006-11-20
US7935718B2 (en) 2011-05-03

Similar Documents

Publication Publication Date Title
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
NO20003233L (no) 4-hydroksykinolin-3-karboksamider og hydrazider som antivirale midler
PT1200412E (pt) Agentes anti-proliferativos de imidazole
ATE408601T1 (de) Fredericamycin-derivate
TR200200204T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
DE60045751D1 (de) Therapeutische Behandlung androgenrezeptorbedingter Leiden
MXPA04001037A (es) Derivados de n-fenilpirrol guanidina como ligandos del receptor de melanocortina.
GB0318447D0 (en) Therapeutic agents
DK1663242T3 (da) 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
GB0222495D0 (en) Compounds
ATE254461T1 (de) Behandlung von augenschmerzen
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
DE69935670D1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
TR200103119T2 (tr) Göz kurumasının tedavisi için madde.
CY1106194T1 (el) Θepαπευτικη αγωγη της δυσκινησιας
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE69912743D1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges
GB0326633D0 (en) Therapeutic agents
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
DK1152760T3 (da) Anvendelse af 4-aminopyridin til behandling af perifere neuropatier
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
ATE406880T1 (de) Behandlung von motorischen veränderungen mit 5- hydrxoytryptamin 1a rezeptor aktivität verstärkenden wirkstoffen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1223930

Country of ref document: EP